Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 22,540 shares of Illumina stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $195.21, for a total value of $4,400,033.40. Following the transaction, the director now directly owns 539,176 shares of the company’s stock, valued at $105,252,546.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of Illumina, Inc. (NASDAQ ILMN) opened at 210.72 on Friday. The firm has a market cap of $30.77 billion, a PE ratio of 42.28 and a beta of 0.81. Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $214.34. The firm’s 50-day moving average price is $197.88 and its 200 day moving average price is $180.42.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. The company had revenue of $662.00 million during the quarter, compared to the consensus estimate of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.86 EPS. Equities analysts anticipate that Illumina, Inc. will post $3.65 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This article was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://ledgergazette.com/2017/09/17/insider-selling-illumina-inc-ilmn-director-sells-4400033-40-in-stock.html.
A number of equities analysts have recently weighed in on ILMN shares. Vetr downgraded Illumina from a “strong-buy” rating to a “buy” rating and set a $197.84 price objective for the company. in a research report on Wednesday, May 31st. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $195.00 price objective for the company in a research report on Thursday, July 27th. Canaccord Genuity raised Illumina from a “hold” rating to a “buy” rating and boosted their price target for the company from $170.00 to $215.00 in a research report on Monday, August 7th. Argus boosted their price target on Illumina from $205.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday. Finally, First Analysis raised Illumina from an “underweight” rating to an “equal weight” rating and set a $176.00 price target for the company in a research report on Wednesday, August 2nd. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $181.76.
Large investors have recently modified their holdings of the stock. Advisory Services Network LLC bought a new position in Illumina in the 1st quarter valued at approximately $117,000. Penserra Capital Management LLC lifted its stake in Illumina by 13.0% in the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after purchasing an additional 102 shares during the last quarter. Paradigm Asset Management Co. LLC lifted its stake in Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after purchasing an additional 50 shares during the last quarter. Patten Group Inc. lifted its stake in Illumina by 2.7% in the 1st quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after purchasing an additional 25 shares during the last quarter. Finally, NN Investment Partners Holdings N.V. lifted its stake in Illumina by 11.3% in the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock valued at $171,000 after purchasing an additional 100 shares during the last quarter. 93.34% of the stock is owned by institutional investors and hedge funds.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.